Physician-supervised programs targeting the progressive decline of stem cell populations, growth factor signaling, and tissue repair mechanisms — using interventions supported by peer-reviewed clinical evidence.
Regenerative Support: Evidence-Based Therapies for Tissue Repair and Renewal
Physician-supervised programs targeting the progressive decline of stem cell populations, growth factor signaling, and tissue repair mechanisms — using interventions supported by peer-reviewed clinical evidence.
Quick summary
- This page explains how we help your tissues heal and renew.
- We use labs and exams to see what your body needs most.
- Care may include peptides, growth factor support, and physical therapy.
- Every plan is led by a licensed doctor and reviewed over time.
Regenerative medicine is concerned with one of the most fundamental questions in biological aging: why does the body become less capable of repairing itself over time, and what can be done about it? The answer involves the progressive decline of stem cell populations, growth factor signaling, tissue repair mechanisms, and the cellular environment that makes regeneration possible. At Advanced Vitality Group, our regenerative support programs target these mechanisms using interventions supported by peer-reviewed clinical evidence — and we are transparent about the distinction between what is well-established and what remains investigational.
Stem cell exhaustion — one of the 12 recognized hallmarks of aging (López-Otín et al., Cell, 2023) — describes the decline in number and function of tissue-resident stem cell populations with age. Satellite cells in skeletal muscle, hematopoietic stem cells in bone marrow, intestinal epithelial stem cells — all of these populations diminish and lose function as we age, impairing the body's ability to repair and renew its tissues. Regenerative support programs work by optimizing the physiological conditions that maintain and support these stem cell populations, rather than introducing exogenous cells.
The Growth Hormone and IGF-1 Axis
Growth hormone (GH) and its primary downstream mediator, insulin-like growth factor 1 (IGF-1), are central regulators of tissue repair, muscle maintenance, bone density, and cellular regeneration. Both decline substantially with age: GH secretion decreases approximately 14% per decade after age 30, and IGF-1 levels fall from peak values in early adulthood to significantly lower levels by age 70 in most individuals. This decline contributes meaningfully to sarcopenia, reduced healing capacity, increased fat accumulation, and loss of bone density.
The strongest clinical evidence for GH axis optimization comes from studies in patients with documented GH deficiency. A systematic review and meta-analysis of 22 randomized controlled trials found that GH replacement in GH-deficient adults significantly improved body composition (increased lean mass, decreased fat mass), bone mineral density, exercise capacity, and quality of life (Maison P et al., European Journal of Endocrinology, 2004). The original Rudman et al. trial (NEJM, 1990), while small, demonstrated compelling effects on body composition in older men.
However, direct GH supplementation in non-deficient adults carries meaningful side effects documented in a 2007 meta-analysis of 31 trials: edema (39%), arthralgias (41%), carpal tunnel syndrome (18%), and new-onset diabetes (6.1%). At Advanced Vitality Group, we do not offer direct GH supplementation to non-deficient patients. Instead, for patients with evidence of GH insufficiency, we use growth hormone secretagogues — agents that stimulate the pituitary to produce GH naturally, preserving the physiological pulsatile release pattern.
What GH/IGF-1 Decline Causes
- Sarcopenia and muscle loss
- Reduced healing capacity
- Increased fat accumulation
- Loss of bone density
- Impaired tissue regeneration
Growth Hormone Secretagogues
Growth hormone secretagogues (GHS) represent a more physiological approach to GH axis optimization than exogenous GH. By stimulating endogenous GH release rather than replacing it externally, secretagogues preserve normal pulsatile secretion patterns and carry a more favorable safety profile for appropriate patients.
Sermorelin (GHRH Analogue)
An FDA-approved synthetic analogue of growth hormone-releasing hormone (GHRH) that stimulates GH secretion from the pituitary. Clinical data show improvements in body composition and sleep quality at doses of 0.2–0.3 mg/day in adults with GH insufficiency (Walker RF, Clinical Interventions in Aging, 2006).
CJC-1295 / Ipamorelin
CJC-1295 is a GHRH analogue with an extended half-life; ipamorelin is a selective GH secretagogue receptor agonist with a favorable cortisol and prolactin profile. Phase 1 data show that CJC-1295 produces sustained GH and IGF-1 elevations. The combination is used clinically in GH insufficiency protocols. Long-term RCT data in healthy aging adults remains limited.
Ibutamoren (MK-677)
An oral GH secretagogue with a 2-year randomized controlled trial (n = 395 older adults) showing significant increases in IGF-1 and GH levels, but no significant functional outcome improvement and an increased incidence of congestive heart failure in the treatment group (Nass R et al., Annals of Internal Medicine, 2008). This study highlights the importance of careful patient selection and monitoring with GH secretagogues.
Peptide Therapy for Tissue Repair
Peptides are short amino acid chains that act as signaling molecules. Several peptides have been investigated for their potential to support tissue repair, wound healing, and regenerative processes:
| Peptide | Primary Evidence | Human RCT Status | Use at AVG |
|---|---|---|---|
| BPC-157 | Multiple animal studies showing tendon/ligament healing, gastroprotection, and angiogenesis | Limited published human RCTs; safety data in humans is preliminary | Discussed individually; investigational status disclosed |
| TB-500 (Thymosin Beta-4) | Animal studies show wound healing acceleration and anti-inflammatory effects; Phase 2 cardiac trials completed | No regulatory approval; cardiac trial data not yet published | Investigational; requires physician evaluation |
| Sermorelin | FDA-approved for GH deficiency in children; adult off-label data available | Phase 2 human data in GH-insufficient adults | Used for documented GH insufficiency |
| Ipamorelin / CJC-1295 | Phase 1/2 data on GH/IGF-1 elevation | Limited but available human data | Used in GH secretagogue protocols |
At Advanced Vitality Group, we apply a consistent standard: before recommending any peptide, we review the available human evidence, communicate its limitations clearly, and ensure full informed consent regarding investigational status where applicable. We do not recommend peptides based on anecdotal reports or marketing claims.
Musculoskeletal Regeneration: The Sarcopenia Problem
Sarcopenia — the progressive, age-related loss of skeletal muscle mass and strength — is one of the most clinically significant consequences of declining regenerative capacity. It begins as early as the third decade, accelerates after age 60, and is independently associated with falls, fractures, metabolic disease, and all-cause mortality. The European Working Group on Sarcopenia in Older People (EWGSOP2) defines sarcopenia by low muscle mass combined with low muscle strength or low physical performance (Cruz-Jentoft AJ et al., Age and Ageing, 2019).
Addressing sarcopenia is a central function of regenerative support programs at Advanced Vitality Group. The interventions with the strongest evidence are not exotic:
Progressive Resistance Training (Grade A Evidence)
The most powerful intervention for preventing and reversing sarcopenia across all age groups. Systematic reviews confirm significant gains in muscle mass, strength, and physical function in older adults with structured resistance training programs.
Protein Optimization (Grade A Evidence)
ESPEN guidelines recommend 1.0–1.2 g per kg of body weight per day for healthy older adults, increasing to 1.2–1.5 g/kg/day for those at nutritional risk. Leucine-rich protein sources (whey, eggs, legumes) are preferred for maximal stimulation of muscle protein synthesis.
Testosterone Optimization (Grade A for Hypogonadal Men)
The Testosterone Trials demonstrated significant improvements in muscle mass, strength, and physical function in older men with low testosterone treated with TRT (Snyder PJ et al., NEJM, 2016). The AUA guidelines support TRT for men with clinically diagnosed hypogonadism.
Frequently Asked Questions About Regenerative Support
Scientific References
- López-Otín C, et al. “Hallmarks of aging: An expanding universe.” Cell. 2023;186(2):243–278.
- Rudman D, et al. “Effects of human growth hormone in men over 60 years old.” NEJM. 1990;323(1):1–6.
- Maison P, et al. “Adult growth hormone deficiency: a systematic review.” European Journal of Endocrinology. 2004;150(6):783–792.
- Liu H, et al. “Systematic review: the effects of growth hormone on athletic performance.” Annals of Internal Medicine. 2008;148(10):747–758.
- Nass R, et al. “Effects of an oral ghrelin mimetic on body composition in healthy older adults.” Annals of Internal Medicine. 2008;149(9):601–611.
- Walker RF. “Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?” Clinical Interventions in Aging. 2006;1(4):307–308.
- Snyder PJ, et al. “Effects of testosterone treatment in older men.” NEJM. 2016;374(7):611–624.
- Cruz-Jentoft AJ, et al. “Sarcopenia: revised European consensus on definition and diagnosis.” Age and Ageing. 2019;48(1):16–31.
- Iranmanesh A, et al. “Age and GH secretory bursts.” Journal of Clinical Endocrinology & Metabolism. 1991;73(5):1081–1088.
More in Longevity Medicine
View allAnti-Aging Medicine
Evidence-based anti-aging protocols grounded in the Hallmarks of Aging framework.
Cellular Repair
Mitochondrial function, autophagy activation, and cellular stress resistance.
Inflammation Control
Treating inflammaging through lifestyle, omega-3s, and targeted medicine.
Longevity Protocols
Comprehensive longevity programs with biomarker tracking and protocol optimization.
Regenerative Support
You are hereTissue repair, growth factor optimization, and cellular regeneration strategies.
Schedule a consultation to evaluate your growth factors, hormone levels, and tissue repair capacity.